GlassScriptPhysician profile
David G Miller
NPI 1992799191
$298,597.67
in general payments reported to CMS, 2019-2025
25 companies · $66K in 2025
The $66K reported for 2025 was more than what 98% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $35K · 2021: $33K · 2022: $69K · 2023: $19K · 2024: $50K · 2025: $66K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $94K · Consulting Fee: $23K · Food and Beverage: $9,618 · Travel and Lodging: $8,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $93,614.09 |
| Consulting Fee | $23,405.81 |
| Food and Beverage | $9,617.59 |
| Travel and Lodging | $8,364.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $198,245.05 | 2019-2025 | Eylea Hd, Eylea |
| US Retina LLC | $62,385.54 | 2019-2022 | |
| Astellas Pharma US INC | $23,399.46 | 2023-2025 | Izervay |
| Allergan, INC. | $3,138.88 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $2,286.89 | 2021-2025 | Syfovre |
| Neurotech Pharmaceuticals, INC. | $2,103.23 | 2025 | |
| Genentech USA, INC. | $1,576.15 | 2019-2025 | Vabysmo, Susvimo |
| Dutch Ophthalmic, USA | $1,278.06 | 2019-2025 | Tissueblue, Eva, Combined Machine |
| Abbvie INC. | $1,191.11 | 2022-2025 | |
| Alimera Sciences, INC. | $722.04 | 2019-2024 | Yutiq, Iluvien |
| Alcon Vision LLC | $375.52 | 2020-2025 | Unity |
| Coherus Oncology, INC. | $362.98 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $271.79 | 2019-2021 | |
| Eyepoint US, INC. | $196.39 | 2019-2023 | |
| Ani Pharmaceuticals, INC. | $163.04 | 2025 | Yutiq, Iluvien |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $153.00 | 2024-2025 | Eylea Hd |
| Mallinckrodt Hospital Products INC. | $147.05 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $129.92 | 2022-2025 | Xipere, Retisert, Visudyne |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $109.46 | 2020 | |
| Carl Zeiss Meditec, INC. | $103.84 | 2019 | |
| Sandoz INC. | $77.16 | 2024-2025 | Cimerli |
| Harrow Eye, LLC | $56.91 | 2024-2025 | Triesence |
| Biogen, INC. | $55.20 | 2022-2023 | |
| Ocular Therapeutix, INC. | $49.85 | 2024 | Dextenza |
| Horizon Therapeutics Plc | $19.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$200,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.